About
Regenerative therapies for orthopedic disorders
Areas of Focus
Categories
Biologics & BiopharmaceuticalStem Cell & Cellular TherapyVirginia, DC, DE & Maryland
Team (14)
David Hunter, Ph.D.
Florance and Cope Chair of Rheumatology at University of Sydney
Kolon TissueGene
board_chair
Diana M. Halim, M.S.
Vice President of Clinical and Regulatory Affairs
Kolon TissueGene
executive
Javad Parvizi, M.D., Ph.D.
Professor of Orthopedic Surgery at Acibadem University, Istanbul
Kolon TissueGene
team_member
Jeremy Hoff, D.O.
EmergeOrtho Coastal Division Physical Medicine and Pain Management; Division Lead Research Investigator
Kolon TissueGene
team_member
Jung In Kim
Chief Financial Officer
Kolon TissueGene
executive
Michael A. Mont, M.D.
Orthopedic Surgeon specializing in Hip and Knee Joint Preservation and Replacement at The Rubin Institute for Advanced Orthopedics
Kolon TissueGene
team_member
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
1,459
By Phase
PHASE1: 2PHASE2: 2PHASE3: 2
By Status
NOT_YET_RECRUITING: 2ACTIVE_NOT_RECRUITING: 2COMPLETED: 2
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06144970Lead Sponsor
Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease
PHASE1Not yet recruiting
24 participants
Started: Nov 1, 2025 · Completed: Nov 1, 2027
NCT05276011Lead Sponsor
A Study to Determine the Safety and Efficacy of TG-C in Subjects with Symptomatic Early Hip Osteoarthritis
PHASE2Not yet recruiting
255 participants
Started: Oct 31, 2025 · Completed: Oct 31, 2026
NCT03291470Lead Sponsor
Study to Determine the Efficacy and Safety of TG-C in Subjects with Kellgren/Lawrence Grade 2 or 3 OA of the Knee
PHASE3Active, not recruiting
531 participants
Started: Dec 9, 2021 · Completed: Mar 6, 2026
NCT03203330Lead Sponsor
A Study to Determine the Safety and Efficacy of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 OA of the Knee
PHASE3Active, not recruiting
535 participants
Started: Oct 30, 2018 · Completed: Jul 10, 2026
NCT01221441Lead Sponsor
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
PHASE2Completed
102 participants
Started: May 31, 2011 · Completed: Oct 31, 2014
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...